胸腔内注药尿激酶加超短波辅助治疗结核性胸膜炎分析.docVIP

胸腔内注药尿激酶加超短波辅助治疗结核性胸膜炎分析 　[摘要] 目的 分析胸腔内注药尿激酶加超短波辅助治疗结核性胸膜炎中的治疗疗效。方法 方便选取2014年5月”2015年9月该院收治的结核性胸膜炎患者70例，将所有患者随机分为两组，均35例。对照组采用常规治疗，观察组则采用胸腔内注药尿激酶加超短波辅助治疗，分析比较两组治疗疗效。结果 观察组治疗有效率为94.3%，显著高于对照组的77.1%，差异有统计学意义（Plt;0.05）；观察组不良反应率为2.9%，对照组不良反应率为5.7%，两组比较差异无统计学意义（Pgt;0.05）。结论 胸腔内注药尿激酶加超短波辅助治疗结核性胸膜炎疗效显著，在临床应用中值得推广。　　[关键词] 胸腔内注药；尿激酶；超短波辅助治疗；结核性胸膜炎　　[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742（2016）07（b）-0111-02　　The Analysis of Tuberculous Pleuritis by Intrapleural Cavity Injection of Urokinase Add the Ultrashort Wave for Adjuvant Therapy　　REN Shu-jun　　Tuberculosis control Institute of Shangqiu City， Shangqiu， Henan Province， 476000 China　　[Abstract] Objective To analyse the treatment effect of tuberculous pleuritis by intrapleural cavity injection of urokinase add the ultrashort wave for adjuvant therapy. Methods Convenient selected 70 cases of patients with tuberculous pleuritis at our hospital from May 2014 to September 2015， randomly divided into two group， each 35 cases. The control group was treated by conventional treatment ， the treatment group was treated by intrapleural cavity injection of urokinase add the ultrashort wave for adjuvant therapy， to analysed the treatment effect of them. Results The effective rate of treatment of the treatment group was 94.3%， that was significantly greater than the 77.1% of the control group， there was statistical significance （P﹤0.05）. The adverse reaction rate of the treatment group was 2.9%， and the adverse reaction rate of the control group was 5.7%， to compared them， there was no statistical significance （Pgt;0.05）. Conclusion That has significant effect of tuberculous pleuritis by intrapleural cavity injection of urokinase add the ultrashort wave for adjuvant therapy， and worth for promotion in the clinical application.　　[Key words] Intrapleural cavity injection； Urokinase； Ultrashort wave for adjuvant therapy； Tuberculous pleuritis　　结合性胸膜炎发病时较急骤，临床表现为胸腔积液、结核的全身中毒症状等[1]。若患者在发病短时间内得不到及时治疗，易导致患者病情更加严重，出现包裹性胸腔积液、肺结核、胸腔畸形，对肺功能造成严重影响，威胁患者